Related references
Note: Only part of the references are listed.Cell cycle control in cancer
Helen K. Matthews et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2022)
BIRB796, an Inhibitor of p38 Mitogen-Activated Protein Kinase, Inhibits Proliferation and Invasion in Glioblastoma Cells
Linyao Zhao et al.
ACS OMEGA (2021)
The p38 Pathway: From Biology to Cancer Therapy
Adrian Martinez-Limon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
MAPKAPK2: the master regulator of RNA-binding proteins modulates transcript stability and tumor progression
Sourabh Soni et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
A novel mutation panel for predicting etoposide resistance in small-cell lung cancer
Zhengang Qiu et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma
Mengjie Guo et al.
FRONTIERS IN ONCOLOGY (2019)
Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin
Yizhu Li et al.
CANCER LETTERS (2018)
Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells
Dauren Alimbetov et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner et al.
CANCER CELL (2017)
Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials
Mario Fiore et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer
Xin Jin et al.
CANCER BIOLOGY & THERAPY (2016)
Molecular mechanisms for tumour resistance to chemotherapy
Shu-Ting Pan et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2016)
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Roberta Visconti et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Extracellular ATP a New Player in Cancer Metabolism: NSCLC Cells Internalize ATP In Vitro and In Vivo Using Multiple Endocytic Mechanisms
Yanrong Qian et al.
MOLECULAR CANCER RESEARCH (2016)
The Stress Kinase p38α as a Target for Cancer Therapy
Ana Igea et al.
CANCER RESEARCH (2015)
Targeting Mitosis in Cancer: Emerging Strategies
Carmen Dominguez-Brauer et al.
MOLECULAR CELL (2015)
The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells
Frederik Koepper et al.
CELL CYCLE (2014)
Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
Israel Canadas et al.
CLINICAL CANCER RESEARCH (2014)
Inhibition of the p38 MAPK pathway sensitizes human gastric cells to doxorubicin treatment in vitro and in vivo
Wei Tan et al.
MOLECULAR MEDICINE REPORTS (2014)
p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance
Valentina Grossi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Inhibition of MK2 shows promise for preventing postoperative ileus in mice
Xiaodong Liu et al.
JOURNAL OF SURGICAL RESEARCH (2013)
Small Cell Lung Cancer
Gregory P. Kalemkerian et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
BIRB796, the Inhibitor of p38 Mitogen-Activated Protein Kinase, Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression Cells
Dan He et al.
PLOS ONE (2013)
Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity
Frederik Koepper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo
Sandra Morandell et al.
CELL REPORTS (2013)
Immunity, inflammation and cancer: a leading role for adenosine
Luca Antonioli et al.
NATURE REVIEWS CANCER (2013)
Calpain-mediated Processing of p53-associated Parkin-like Cytoplasmic Protein (PARC) Affects Chemosensitivity of Human Ovarian Cancer Cells by Promoting p53 Subcellular Trafficking
Michael G. Woo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer Therapy
Razmik Mirzayans et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
Targeting Mutant p53 in Human Tumors
Brian D. Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma
Salome Paillas et al.
CANCER RESEARCH (2011)
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
Cynthia X. Ma et al.
TRENDS IN MOLECULAR MEDICINE (2011)
p53 Activates Either Survival or Apoptotic Signaling Responses in Lupulone-Treated Human Colon Adenocarcinoma Cells and Derived Metastatic Cells
Virginie Lamy et al.
TRANSLATIONAL ONCOLOGY (2010)
Aqueous Versus Non-Aqueous Salt Delivery Strategies to Enhance Oral Bioavailability of a Mitogen-Activated Protein Kinase-Activated Protein Kinase (MK-2) Inhibitor in Rats
Po-Chang Chiang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Signal integration by JNK and p38 MAPK pathways in cancer development
Erwin F. Wagner et al.
NATURE REVIEWS CANCER (2009)
Pyrrolo-pyrimidones: A novel class of MK2 inhibitors with potent cellular activity
Achim Schlapbach et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
N. Bucher et al.
BRITISH JOURNAL OF CANCER (2008)
Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2)
David R. Anderson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue et al.
NATURE (2007)
p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage
H. Christian Reinhardt et al.
CANCER CELL (2007)
Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D
L. Hui et al.
ONCOGENE (2006)
p38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65
Beibei Cai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
SW480, a p53 double-mutant cell line retains proficiency for some p53 functions
PJ Rochette et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation
IA Manke et al.
MOLECULAR CELL (2005)
The p38-mediated stress-activated checkpoint - A rapid response system for delaying progression through antephase and entry into mitosis
A Mikhailov et al.
CELL CYCLE (2005)
Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway
A Mikhailov et al.
JOURNAL OF CELL BIOLOGY (2004)
Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints
H Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The IARC TP53 database: New Online mutation analysis and recommendations to users
M Olivier et al.
HUMAN MUTATION (2002)
ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1
H Zhao et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Share Paper
